Bendamustine combined with donor lymphocytes infusion in hodgkin's lymphoma relapsing after allogeneic hematopoietic stem cell transplantation

Research output: Contribution to journalArticlepeer-review

Abstract

The management of Hodgkin's lymphoma (HL) recurring after allogeneic stem cell transplantation is challenging. We retrospectively describe 18 adults treated with bendamustine followed by escalated donor lymphocyte infusion. Hematological toxicity was manageable (39% grade III to IV neutropenia and 28% grade III to IV thrombocytopenia). The overall response rate was 55%, with 3 complete and 7 partial responses. Median overall and progression-free survival were 11 (range, 1 to 52) and 6 (range, 1 to 28) months, respectively. One-year overall survival of responders (complete or partial) was 70% (95% confidence interval, 42% to 98%), although it was only 16% for nonresponders (n=8). Our data show that bendamustine followed by donor lymphocyte infusion is feasible and can be efficacious as salvage treatment in HL relapsing after an allograft.

Original languageEnglish
Pages (from-to)1444-1447
Number of pages4
JournalBiology of Blood and Marrow Transplantation
Volume20
Issue number9
DOIs
Publication statusPublished - 2014

Keywords

  • Allogeneic stem cell transplantation
  • Bendamustine
  • Donor lymphocyte infusion
  • Hodgkin's lymphoma

ASJC Scopus subject areas

  • Transplantation
  • Hematology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Bendamustine combined with donor lymphocytes infusion in hodgkin's lymphoma relapsing after allogeneic hematopoietic stem cell transplantation'. Together they form a unique fingerprint.

Cite this